局限期前列腺癌的大分割放射治疗:ASTRO、ASCO和AUA循证指南执行摘要
该指南由美国放射肿瘤学会(ASTRO)召集工作组,基于系统文献综述和预设共识方法,针对局限期前列腺癌的中度大分割(每次240-340 cGy)和超大分割(每次500 cGy或以上)放疗的适应证、剂量分割及技术问题提出推荐。基于高质量证据,强烈共识推荐各风险组选择外照射放疗的患者可接受中度大分割;条件性推荐低危和中危患者可考虑超大分割,但强烈鼓励中危患者参加临床试验或多机构登记;条件性不推荐高危患者常规使用超大分割外照射放疗;强烈推荐图像引导放疗并避免非调强三维适形技术。
要点
- 各风险组选择外照射放疗的患者,基于高质量证据强烈共识推荐中度大分割放疗。
- 低危和中危前列腺癌条件性推荐可考虑超大分割放疗,中危患者强烈鼓励参加临床试验或多机构登记。
- 高危患者条件性不推荐常规使用超大分割外照射放疗。
核心结论
- 大分割放疗为患者提供成本和便利方面的重要潜在优势,本推荐旨在为局限期前列腺癌的中度大分割和超大分割提供指导。
- 当前证据基础有限,尤其是超大分割,突出支持大规模随机临床试验的必要性,并强调临床医生与患者共同决策的重要性。
研究设计与样本
- 美国放射肿瘤学会(ASTRO)召集工作组,基于系统文献综述,采用预设共识构建方法和学会批准的证据质量与推荐强度分级工具,针对8个关键问题制定推荐。
主要发现
- 基于高质量证据,达成强烈共识:各风险组选择外照射放疗的患者可接受中度大分割(每次240-340 cGy)。
- 工作组条件性推荐低危和中危前列腺癌可考虑超大分割放疗(每次500 cGy或以上),但强烈鼓励中危患者参加临床试验或多机构登记。
- 高危患者条件性不推荐常规使用超大分割外照射放疗。
- 任何大分割方案均强烈推荐图像引导放疗,并避免非调强三维适形技术。
关键数值与推荐
- 中度大分割定义为每次240-340 cGy。
- 超大分割定义为每次500 cGy或以上。
- 各风险组选择外照射放疗的患者,基于高质量证据强烈共识推荐中度大分割。
- 低危和中危前列腺癌条件性推荐可考虑超大分割放疗,中危患者强烈鼓励参加临床试验或多机构登记。
- 高危患者条件性不推荐常规使用超大分割外照射放疗。
临床怎么用
- 各风险组选择外照射放疗的患者,基于高质量证据强烈共识推荐中度大分割放疗。
- 低危和中危前列腺癌条件性推荐可考虑超大分割放疗,中危患者强烈鼓励参加临床试验或多机构登记。
- 高危患者条件性不推荐常规使用超大分割外照射放疗。
- 任何大分割方案均强烈推荐图像引导放疗,并避免非调强三维适形技术。
局限性
- 当前证据基础有限,尤其是超大分割,突出支持大规模随机临床试验的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer. METHODS AND MATERIALS: The American Society for Radiation Oncology convened a task force to address 8 key questions on appropriate indications and dose-fractionation for moderately and ultrahypofractionated radiation therapy, as well as technical issues, including normal tissue dose constraints, treatment volumes, and use of image guided and intensity modulated radiation therapy. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and Society-approved tools for grading evidence quality and recommendation strength. RESULTS: Based on high-quality evidence, strong consensus was reached for offering moderate hypofractionation across risk groups to patients choosing external beam radiation therapy. The task force conditionally recommends ultrahypofractionated radiation may be offered for low- and intermediate-risk prostate cancer but strongly encourages treatment of intermediate-risk patients on a clinical trial or multi-institutional registry. For high-risk patients, the task force conditionally recommends against routine use of ultrahypofractionated external beam radiation therapy. With any hypofractionated approach, the task force strongly recommends image guided radiation therapy and avoidance of nonmodulated 3-dimensional conformal techniques. CONCLUSIONS: Hypofractionated radiation therapy provides important potential advantages in cost and convenience for patients, and these recommendations are intended to provide guidance on moderate hypofractionation and ultrahypofractionation for localized prostate cancer. The limits in the current evidentiary base-especially for ultrahypofractionation-highlight the imperative to support large-scale randomized clinical trials and underscore the importance of shared decision making between clinicians and patients.
引用
- Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol. 2018. PMID: 30322661. doi:10.1016/j.prro.2018.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。